Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744092 · ClinicalTrials.gov registry record · NA
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
A NA study of Cancer and Venous Thromboembolism, sponsored by Alliance Foundation Trials.
- Completed
- Registry status
- NA
- Development phase
- 811
- Enrollment target
- 20
- Study locations
NCT02744092: Completed NA study of Cancer and Venous Thromboembolism, sponsored by Alliance Foundation Trials.
NCT02744092 is a NA study of Cancer and Venous Thromboembolism that has completed, run by Alliance Foundation Trials. The registered enrollment target is 811 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02744092, a NA study of Cancer and Venous Thromboembolism, has completed, sponsored by Alliance Foundation Trials.
- COMPLETED
- Registry status
- NA
- Development phase
- 811 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin. The information gained will empower cancer patients and physicians to make more informed choices about anticoagulation strategies to manage VTE.
Primary Outcome
To compare the effectiveness of anticoagulation with a DOAC (intervention) with LMWH/warfarin (comparator) for preventing VTE recurrence in patients with cancer based on cumulative VTE recurrence reported by patients or clinicians at 6 months. Only VTEs that were nonfatal were considered because of the challenges of attributing cause of death in cancer patients to tumor progression vs. VTE.
Conditions Studied
Interventions
- DRUG Apixaban
- DRUG Warfarin
- DRUG Rivaroxaban
- DRUG Edoxaban
- DRUG Dabigatran
Study Locations (20)
California
- South County Hematology - Chula Vista
- Sharp Rees-Stealy - Chula Vista
- Washington Hospital Healthcare System - Fremont
- Washington Hospital - Fremont
- VA Central California Fresno Medical Center - Fresno
- Cancer Center Oncology Medical Group - La Mesa
- Medical Oncology Associates- San Diego - San Diego
- Sharp Memorial Hospital - San Diego
- Sharp Rees-Stealy - San Diego
- UCSF Medical Center - Mission Bay - San Francisco
- Saint Joseph's Medical Center - Stockton
Florida
- Morton Plant Hospital - Clearwater
- Breast Cancer Center at Memorial Regional Hospital - Hollywood
- Memorial Cancer Institute at Memorial Regional Hospital - Hollywood
- Memorial Regional Hospital - Hollywood
- Hollis Cancer Center - Lakeland
- Breast Cancer Center at Memorial Hospital West - Pembroke Pines
- Memorial Cancer Institute at Memorial Hospital West - Pembroke Pines
Connecticut
- Middlesex Hospital - Middletown
- The Stamford Hospital - Stamford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 811 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2021-02-22 |
| Phase | NA |
What the finished NCT02744092 record still lists
NCT02744092 is an interventional study that assigns participants to a tested intervention. The registered 811 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (77% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Apixaban is the first listed.
NCT02744092 names 20 study sites across 3 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02744092 about?
NCT02744092 is a clinical study titled "Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer". The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The compara...
What is the current status of trial NCT02744092?
This trial is currently completed. It is a NA study. The enrollment target is 811 participants. The study started on 2016-12-13. Estimated completion is 2021-02-22.
What conditions does trial NCT02744092 study?
This clinical trial studies the following conditions: Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot.
What interventions are being tested in trial NCT02744092?
The interventions under investigation include: Apixaban (DRUG), Warfarin (DRUG), Rivaroxaban (DRUG), Edoxaban (DRUG), Dabigatran (DRUG).
Who is sponsoring clinical trial NCT02744092?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02744092 being conducted?
This trial has 20 study locations across California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02744092's enrollment target sits among peer trials
811 93rd of 615 higher than 523 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI